Insider Sale: Director Arthur Ryan Sells Shares of Regeneron Pharmaceuticals Inc (REGN)
Regeneron Pharmaceuticals(REGN.US) Director Sells US$105.92K in Common Stock
$Regeneron Pharmaceuticals(REGN.US)$ Director RYAN ARTHUR F sold 100 shares of common stock on Jul 1, 2024 at an average price of $1,059.24 for a total value of $105.92K.Source: Announcement What is s
Regeneron Pharmaceuticals(REGN.US) Officer Sells US$1.19 Million in Common Stock
$Regeneron Pharmaceuticals(REGN.US)$ Officer McCourt Marion sold 1,137 shares of common stock on Jul 1, 2024 at an average price of $1,047.11 for a total value of $1.19 million.Source: Announcement Wh
Looking Into Regeneron Pharmaceuticals's Recent Short Interest
Regeneron Pharmaceuticals's (NYSE:REGN) short percent of float has risen 5.99% since its last report. The company recently reported that it has 1.85 million shares sold short, which is 1.77% of all re
Regeneron Pharmaceuticals Insider Sold Shares Worth $1,190,564, According to a Recent SEC Filing
Marion McCourt, Executive Vice President, Commercial, on July 01, 2024, sold 1,137 shares in Regeneron Pharmaceuticals (REGN) for $1,190,564. Following the Form 4 filing with the SEC, McCourt has cont
Regeneron Pharmaceuticals on Pace for Largest Percent Decrease Since November 2023 -- Data Talk
Regeneron Pharmaceuticals, Inc. (REGN) is currently at $1033.16, down $23.86 or 2.26% --Would be lowest close since June 13, 2024, when it closed at $1026.55 --On pace for largest percent decrease s
Express News | Shares of Pharmaceutical Stocks Are Trading Lower After Biden Called on Novo Nordisk to Cut Ozempic and Wegovy Prices
Insiders At Regeneron Pharmaceuticals Sold US$26m In Stock, Alluding To Potential Weakness
Form 144 | Regeneron Pharmaceuticals(REGN.US) Officer Proposes to Sell 1.19 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Jul 1, $Regeneron Pharmaceuticals(REGN.US)$ Officer MARION E MCCOURT intends to sell 1,137 shares of its common stock on Jul 1, with a total market value of approximately $1.19
What's Going On With Regeneron Pharmaceuticals Stock On Friday?
On Friday, Regeneron Pharmaceuticals Inc (NASDAQ:REGN) announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion recommending conditi
CHMP Recommends Regeneron Lymphoma Antibody Drug for Conditional Approval
Regeneron's Odronextamab Receives Opinion From EMA for Lymphoma Treatment
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommendi
Express News | Odronextamab Recommended for EU Approval by the Chmp to Treat Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-Cell Lymphoma
Regeneron Pharma Is Maintained at Buy by Canaccord Genuity
Regeneron Pharma Is Maintained at Buy by Canaccord Genuity
First Inhaled COPD Therapy In Over 2 Decades - FDA Approves Verona Pharma's First Commercial Product
On Wednesday, the FDA approved Verona Pharma plc's (NASDAQ:VRNA) Ohtuvayre (ensifentrine) for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients.Ohtuvayre is t
Express News | Canaccord Genuity Maintains Buy on Regeneron Pharmaceuticals, Maintains $1152 Price Target
CCORF Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,152
CCORF analyst John Newman maintains $Regeneron Pharmaceuticals(REGN.US)$ with a buy rating, and maintains the target price at $1,152.According to TipRanks data, the analyst has a success rate of 38.3%
Regeneron, Sanofi Eosinophilic Esophagitis Treatment Showed Improvements for Children in Phase 3 Study
Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) said Wednesday that a phase 3 trial showed that a greater proportion of children with eosinophilic esophagitis receiving their drug Dupixent showed "s
Regeneron to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2024
TARRYTOWN, N.Y., June 27, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its second quarter 2024 financial and operating results on Thurs
Express News | Dupixent® (Dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age With Eosinophilic Esophagitis Published in the New England Journal of Medicine